Eurosurveillance · 2018 · 29 citations · 19 references
Veterinary MedicineInfectious DiseasesPediatricsImmunizationInfectious Disease EpidemiologyVaccinologyAdult ImmunizationImmunization EpidemiologyPediatric ImmunizationVaccinationVaccine EffectivenessVaccine-preventable DiseasesEpidemiological ConfirmationMeasles-mumps-rubella VaccinationMedian AgeMumps VaccinationOutbreak ConfirmationRelative Risk EstimationRelative Risk ReductionVaccine-preventable Disease Surveillance
From 6 September 2015-May 2016, a large mumps outbreak occurred among vaccinated students in Norway. A case was defined as a person presenting with a clinical mumps infection, notified between 1 September 2015 and 30 June 2016. Confirmed cases had positive laboratory confirmation and probable cases had an epidemiological link; PCR-positive specimens were genotyped. A total of 232 cases were notified (230 confirmed) with median age of 23 years (range 4-81) and 61% were male. Of 68 (30%) confirmed cases that were genotyped, 66 were genotype G and associated with the outbreak. Cases that had received two doses of the measles-mumps-rubella (MMR) vaccine had reduced risk of hospitalisation (adjusted relative risk (aRR): 0.14; 95%CI: 0.03-0.57), mumps-related orchitis (aRR: 0.21; 95% CI: 0.08-0.55) and severe outcome (aRR: 0.25; 95% CI: 0.10-0.62) compared with those unvaccinated. A third dose of the vaccine was offered to approximately 1,300 fully vaccinated close contacts and subsequently reported cases decreased. This large outbreak, occurring among predominately vaccinated students, suggests the current genotype A vaccine offers suboptimal protection against mumps genotype G. We recommend maintaining high vaccination coverage and offering the vaccine to all unvaccinated individuals.
19
Recent Resurgence of Mumps in the United States
Gustavo H. Dayan, M. Patricia Quinlisk, Amy A. Parker et al. · New England Journal of Medicine · 2008 · 402 citations · Full text